|1.||Masuyama, Tohru: 2 articles (01/2012 - 10/2005)|
|2.||Yamamoto, Kazuhiro: 2 articles (01/2012 - 10/2005)|
|3.||Kim, S G: 2 articles (04/2001 - 01/2001)|
|4.||Lee, M G: 2 articles (04/2001 - 01/2001)|
|5.||Kim, S H: 2 articles (04/2001 - 01/2001)|
|6.||Kwon, J W: 2 articles (04/2001 - 01/2001)|
|7.||Cho, M K: 2 articles (04/2001 - 01/2001)|
|8.||Kim, Y G: 2 articles (04/2001 - 01/2001)|
|9.||Ernst, Michael E: 1 article (01/2014)|
|10.||Kaur, Ramdeep: 1 article (01/2014)|
|1.||Body Weight (Weight, Body)
04/13/2001 - "After intravenous administration to rats with PCMC, the total amount of 8-hr urinary excretion of unchanged azosemide was significantly greater (457 versus 305 microg/g body weight), however, the 8-hr urine output (15.3 versus 31.1 ml/g kidney) was not significantly different between control rats and rats with PCMC. "
10/01/1996 - "After oral administration of azosemide, the 8-h urine output decreased significantly in the AIDRs (9.32 compared with 16.1 mL per 100 g body weight) because of the significantly reduced 8-h urinary excretion of azosemide (3.00 compared with 9.14% of oral dose). "
06/08/1985 - "In the 1st group, Azosemide brought about a significant reduction in arterial pressure, without modifying body weight, but caused considerable weight loss (from 71 to 64 kg) (P less than 0,01) in the oedema patients without altering arterial pressure. "
10/01/2001 - "Blood pressure, body weight, renal function and echocardiographic findings were the same during the furosemide and azosemide treatments. "
07/01/1997 - "The content of hepatic cytochrome P-450 (0.751 versus 1.57 nmol/mg protein) and the weight of liver (3.53 versus 4.20% of body weight) increased significantly in 3-MC pretreated rats, suggesting that the metabolizing enzyme(s) for azosemide seemed to be induced by pretreatment with 3-MC. "
01/01/2012 - "The purpose of this study was to compare the therapeutic effects of furosemide and azosemide, a short- and long-acting loop diuretic, respectively, in patients with chronic heart failure (CHF). "
05/01/2012 - "We conducted a multicenter, randomized, controlled trial in order to compare the therapeutic effects of azosemide, a long-acting loop diuretic, and furosemide, a short-acting one, on neurohumoral factors and cardiac function in outpatients with chronic heart failure (CHF). "
06/01/2009 - "Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide."
10/01/2005 - "Azosemide provided better prognosis in heart failure rats compared with furosemide, partly through attenuation of the reflex increase in cardiac sympathetic neuronal activity caused by the development of heart failure. "
10/01/2001 - "We evaluated the comparative effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting loop diuretic, on neurohumoral factors and quality of life (QOL) in patients with congestive heart failure (CHF). "
|3.||Weight Loss (Weight Reduction)
|4.||Hypertension (High Blood Pressure)
06/08/1985 - "The results of a study conducted using a new loop diuretic, Azosemide, on a group of 45 patients suffering from hypertension and oedema are reported. "
10/01/2003 - "Azosemide is used in the treatment of oedematous states and hypertension. "
02/19/1981 - "The effect of repeated Azosemide infusions (20 mg in 500 ml 5% glucose for one h) on urine volume and electrolyte excretion, and on the activity of the renin-angiotensin-aldosterone system (RAAS) was studied in a group of 15 patients with benign essential hypertension before and during treatment with the beta-adrenergic blocker Trimepranol. "
09/01/2005 - "Azosemide could effectively lessen edema, improve heart function and decrease ascitesûit is well tolerated and is particularly useful for the diuretic treatment."
09/01/2005 - "To assess the efficacy and safety of azosemide in patients with edema and ascites. "
09/01/2005 - "[Efficacy and safety of azosemide in patients with edema and ascites]."
09/01/2005 - "At the end of the study, the weight changes were (2.87+/-3.10) kg and (2.81 +/-2.84) kg; the total effective rate of edema lessen was 89.19% and 89.81%; the total effective rate of heart function improvement was 64.44% and 66.66%; the 24 h urine output increased (321.85 +/-669.52) ml and (273.80 +/-645.72) ml for azosemide and furosemide, respectively. "
09/01/2005 - "The dosage were adjusted to azosemide 60 mg/d (cardiac, renal edema), 90 mg (hepatogeic edema); or furosemide 40 mg/d (cardiac, renal edema), 60 mg (hepatogeic edema), if diuretic effects were not obtained at the end of third day. "
|3.||Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)
|4.||Adrenergic Antagonists (Antiadrenergic Agents)
|9.||Atrial Natriuretic Factor (ANF)